ALZN - Alzamend Neuro, Inc.
1.98
0.030 1.515%
Share volume: 29,977
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.14%
PREVIOUS CLOSE
CHG
CHG%
$1.95
0.03
0.02%
View ratios
| Fiscal Date | 01-31-2024 | 04-30-2024 | 07-31-2024 | 10-31-2024 | |
|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2024 | Q4 2024 | Q1 2024 | Q2 2024 | |
| Report Date | 03-25-2024 | 07-22-2025 | 09-11-2024 | 12-11-2024 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | ||||
| Operating expenses | 2.660 M | 4.016 M | 962.405 K | 1.358 M | |
| Selling general and admin | 751.173 K | 685.460 K | 755.834 K | 1.047 M | |
| Research and development | 1.909 M | 3.331 M | 206.571 K | 311.088 K | |
| Total expenses | 2.660 M | 4.016 M | 962.405 K | 1.358 M | |
| 50.99% | -76.04% | 41.11% | |||
| Operating income | -2.660 M | -4.016 M | -962.405 K | -1.358 M | |
| Ebit | -2.660 M | -4.016 M | -962.405 K | -1.362 M | |
| Pretax income | -2.662 M | -4.015 M | -974.411 K | -1.365 M | |
| 50.82% | -75.73% | 40.09% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -2.662 M | -4.019 M | -974.411 K | -1.362 M | |
| -50.95% | 75.75% | -39.73% |